Vanguard Group’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $87.8M | Buy |
11,186,677
+1,358,760
| +14% | +$10.7M | ﹤0.01% | 1924 |
|
|
2025
Q3 | $80M | Buy |
9,827,917
+10,980
| +0.1% | +$72.9K | ﹤0.01% | 1952 |
|
|
2025
Q2 | $45.8M | Buy |
9,816,937
+1,707,293
| +21% | +$7.82M | ﹤0.01% | 2160 |
|
|
2025
Q1 | $44.5M | Buy |
8,109,644
+210,581
| +3% | +$850K | ﹤0.01% | 2139 |
|
|
2024
Q4 | $26.8M | Buy |
7,899,063
+133,738
| +2% | +$430K | ﹤0.01% | 2444 |
|
|
2024
Q3 | $22.1M | Buy |
7,765,325
+108,435
| +1% | +$278K | ﹤0.01% | 2545 |
|
|
2024
Q2 | $17.2M | Buy |
7,656,890
+50,648
| +0.7% | +$102K | ﹤0.01% | 2646 |
|
|
2024
Q1 | $16.8M | Buy |
7,606,242
+519,897
| +7% | +$1.35M | ﹤0.01% | 2684 |
|
|
2023
Q4 | $16.7M | Buy |
7,086,345
+60,181
| +0.9% | +$111K | ﹤0.01% | 2676 |
|
|
2023
Q3 | $13.1M | Buy |
7,026,164
+74,565
| +1% | +$171K | ﹤0.01% | 2724 |
|
|
2023
Q2 | $18.2M | Buy |
6,951,599
+110,515
| +2% | +$281K | ﹤0.01% | 2632 |
|
|
2023
Q1 | $11.2M | Buy |
6,841,084
+243,128
| +4% | +$304K | ﹤0.01% | 2877 |
|
|
2022
Q4 | $8.78M | Buy |
6,597,956
+88,223
| +1% | +$125K | ﹤0.01% | 3012 |
|
|
2022
Q3 | $10.2M | Buy |
6,509,733
+216,252
| +3% | +$358K | ﹤0.01% | 2945 |
|
|
2022
Q2 | $9.69M | Buy |
6,293,481
+1,085,295
| +21% | +$2.29M | ﹤0.01% | 3004 |
|
|
2022
Q1 | $13.3M | Buy |
5,208,186
+92,563
| +2% | +$226K | ﹤0.01% | 3000 |
|
|
2021
Q4 | $15M | Buy |
5,115,623
+2,139,443
| +72% | +$4.62M | ﹤0.01% | 2990 |
|
|
2021
Q3 | $7.29M | Sell |
2,976,180
-4,187
| -0.1% | -$12.2K | ﹤0.01% | 3425 |
|
|
2021
Q2 | $12.1M | Buy |
2,980,367
+234,322
| +9% | +$894K | ﹤0.01% | 3111 |
|
|
2021
Q1 | $12.4M | Buy |
2,746,045
+332,997
| +14% | +$1.8M | ﹤0.01% | 3034 |
|
|
2020
Q4 | $11.9M | Buy |
2,413,048
+187,643
| +8% | +$939K | ﹤0.01% | 2907 |
|
|
2020
Q3 | $13.2M | Buy |
2,225,405
+58,161
| +3% | +$233K | ﹤0.01% | 2650 |
|
|
2020
Q2 | $5.76M | Buy |
2,167,244
+475,407
| +28% | +$1.66M | ﹤0.01% | 3034 |
|
|
2020
Q1 | $3.3M | Buy |
1,691,837
+373,777
| +28% | +$1.61M | ﹤0.01% | 3151 |
|
|
2019
Q4 | $9.29M | Buy |
1,318,060
+23,531
| +2% | +$194K | ﹤0.01% | 2893 |
|
|
2019
Q3 | $12.7M | Buy |
1,294,529
+75,376
| +6% | +$847K | ﹤0.01% | 2703 |
|
|
2019
Q2 | $13.9M | Buy |
1,219,153
+81,209
| +7% | +$853K | ﹤0.01% | 2680 |
|
|
2019
Q1 | $11.4M | Buy |
1,137,944
+809,635
| +247% | +$10.4M | ﹤0.01% | 2756 |
|
|
2018
Q4 | $5.58M | Buy |
328,309
+73,245
| +29% | +$1.47M | ﹤0.01% | 3039 |
|
|
2018
Q3 | $4.48M | Buy |
255,064
+230,064
| +920% | +$4.99M | ﹤0.01% | 3276 |
|
|
2018
Q2 | $474K | Buy |
+25,000
| New | +$486K | ﹤0.01% | 3830 |
|
Other funds holding XERS
DCM
N
RA
Vanguard Group's XERS Position: Q4 2025 in Review
Vanguard Group increased its Xeris Biopharma Holdings (XERS) stake by 14% in Q4 2025, buying an estimated $10.7M and bringing the position to 11,186,677 shares worth $87.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1924.
Vanguard Group first reported a position in XERS in Q2 2018 and has held it in 31 quarters since. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.
- Vanguard Group held 11,186,677 shares of Xeris Biopharma Holdings worth $87.8M as of Q4 2025.
- Vanguard Group bought 1,358,760 Xeris Biopharma Holdings shares in Q4 2025, an estimated $10.7M.
- Xeris Biopharma Holdings made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1924 holding.
- Vanguard Group first reported a position in Xeris Biopharma Holdings in Q2 2018 and has held it in 31 quarters since.
- 225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.